SEvere MAlaria treatment with Rectal artesunate and Artemisinin-based Combinatio...
SEvere MAlaria treatment with Rectal artesunate and Artemisinin-based Combination Therapy [in remote settings]
Annually, almost 500,000 children under 5 years die from malaria in Africa. Timely access to effective antimalarial therapies is life saving as treatment with pre-referral rectal artesunate (RAS), followed by injectable artesunate...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
ASAAP-plus
Clinical evaluation of AntimalarialS tri-therapy with AtovAq...
1M€
Cerrado
UltiMalVax
A Vaccine Targeting Eradication of Malaria
3M€
Cerrado
STOP2030
STOP 2030: TOWARDS THE INTERRUPTION OF TRANSMISSION OF SOIL-...
4M€
Cerrado
SAF2016-76080-R
CARACTERIZACION DE LOS GLICOCONJUGADOS PRESENTES EN LAS SUPE...
97K€
Cerrado
STROGHAT
Stop transmission of gambiense human African trypanosomiasis
4M€
Cerrado
Información proyecto SEMA ReACT
Duración del proyecto: 48 meses
Fecha Inicio: 2023-03-07
Fecha Fin: 2027-03-31
Líder del proyecto
UNIVERSITEIT ANTWERPEN
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
4M€
Descripción del proyecto
Annually, almost 500,000 children under 5 years die from malaria in Africa. Timely access to effective antimalarial therapies is life saving as treatment with pre-referral rectal artesunate (RAS), followed by injectable artesunate and 3 days treatment with ACTs leads to an observed 96% reduction in mortality. Though recommended by the WHO for years, RAS deployment is very limited.
The full treatment paradigm is not always feasible when access to primary healthcare facilities is limited due to lack of transport, non-availability of services, and cost. Rollout has recently been paused as outcomes data is incomplete in these contexts making the development of best practice recommendations challenging. Hence the relevance of the proposed study.
The proposed project is an observational, non-inferiority study in Zambia and DRC. Community Health Care Workers will identify/diagnose, treat and follow up patients with (severe) malaria as part of integrated community case management. We will compare the efficacy of a treatment regimen consisting of pre-referral RAS, then post-referral injectable artesunate, followed by three days of ACT versus a regimen consisting of RAS alone followed by three days of ACT in remote areas. We will compare recurrence rate between the two regimens at Day 28, the number of lives saved, the risk of generating drug resistance. We will assess and mitigate operational and institutional facilitators and barriers in all stakeholders (patients, caregivers, health care providers, regulators, malaria experts) and recommend sustainable policies for this remote context. This generated evidence will support policy development and implementation.
The proposed consortium brings together vital experience in the rollout and deployment of rectal artesunate, study design and execution, social science, data collection and management, stakeholder engagement and translation of research results into clinical practice.